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Clinicopathological and
immunohistochemical study of 29 cases of
solid-pseudopapillary neoplasms of the
pancreas in patients under 20 years of age
along with detailed review of literature
Nasir Ud Din1, Shabina Rahim1, Jamshid Abdul-Ghafar2* , Arsalan Ahmed1 and Zubair Ahmad1
Abstract
Background: Pancreatic Solid Pseudopapillary Neoplasms (SPNs) are rare low-grade malignant tumors with a
marked preponderance for young females. Objective was to describe the morphology, differential diagnosis, and
prognosis of SPNs in patients under 20 years of age and present a detailed review of literature.
Methods: A total of 29 cases in patients under 20 years of age reported as SPN during the period January 2014 to
December 2019, were included in the study. These included 19 resection specimens, 4 incision biopsies and 6 cases
received as blocks for second opinion. Hematoxylin and eosin (H&E) slides as well as immunohistochemistry (IHC)
slides of all cases were retrieved and reviewed by the authors. TFE3 and Progesterone Receptor were performed
retrospectively.
Results: Twenty-eight of the 29 patients were females. Ages of patients ranged from 12 to 19 years. Nineteen cases
were resections. Tail was the commonest location. Mean tumor size was 9.5 cm. In 89.5% cases, tumor was confined
to the pancreas. In 2 cases, distant metastasis was present. In 2 cases, extension beyond pancreas was seen. Solid
and pseudopapillary areas were seen in all cases while other features were variable. Beta catenin and Cyclin D1
were positive in most cases while TFE3 was positive in 57% cases. Progesterone Receptor (PR) was positive in all 13
cases in which it was performed. Follow up was available in 14 patients. Follow up period ranged from 3 to 70
months. Twelve were alive and well without recurrence or metastasis while 2 were alive with recurrence and
metastasis to liver and omentum respectively.
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Conclusions: Although many studies on SPNs have been published, surgeons, oncologists and even pathologists in
this part of the world are often not aware of these rare tumors leading to inaccuracies and delays in diagnosis. In
addition, this paper focusses on the interesting observation that the majority of SPNs diagnosed in our department
during study period occurred in patients under 20 years of age (29 versus 21 in patients over 20). However, clinico-
epidemiological, morphologic and prognostic features were similar in both age groups. Possibility of SPNs should
always be considered in case of pancreatic neoplasms occurring in patients under 20 years of age as well. We
believe that this is a very interesting and helpful study for the clinicians as well as the pathologists.
Keywords: Pancreas, Solid pseudopapillary neoplasm (SPN), Young females, Low-grade malignant tumor, Excellent
prognosis, TFE3, Progesterone receptor
Background
Solid pseudopapillary neoplasms (SPNs) of the pancreas
are defined by the new 5th edition of the World Health
Organization (WHO) Classification of Digestive System
Tumors as low grade malignant tumors composed of
poorly cohesive epithelial cells which form solid and
pseudopapillary structures and lack a specific line of
pancreatic epithelial differentiation [1]. SPNs were first
described by Frantz in 1959 as pancreatic papillary cystic
tumors [2]. WHO first classified SPNs in 1996 as solid
pseudopapillary tumors and re-classified them in 2010
as SPNs [3, 4]. SPNs are rare tumors comprising only 1
to 3% of all pancreatic tumors and show a marked fe-
male preponderance and excellent prognosis [5]. Various
studies have reported mean age at diagnosis ranging
from 24 to 39 years and age range of 7 to 83 years [6–
18]. Cases in children, older patients and males have also
been reported [19]. SPNs grow slowly and may become
considerably large before they cause symptoms. Some
patients may present with ill defined, mild upper abdom-
inal pain, while others are asymptomatic. SPNs usually
come to light on abdominal ultrasound or Computed
Tomography (CT) scan performed in patients with per-
sistent, long standing, unexplained upper abdominal
pain. At other times, SPNs are discovered incidentally
during imaging studies performed for some other rea-
son. Owing to their often-silent nature, they may be
quite bulky when first discovered [1, 20]. SPNs do not
show preference for any specific part of the pancreas [9].
In Wang et al’s series, 38.1% cases were located in the
head of pancreas while 49.5% were localized to the body
and tail [8]. This predilection for the head or tail was
also noted in several other studies [12, 14, 21]. Grossly,
SPNs are usually solitary [15], encapsulated and typically
sharply demarcated from adjacent non neoplastic pan-
creatic tissue. Surgical removal is usually easy, and enu-
cleation of the tumor is often performed especially in
tumors smaller than 5 cm in size [8, 12]. All resected tu-
mors in our study were nodular and circumscribed and
partly or wholly encapsulated. Various studies have re-
ported wide variations in tumor size ranging from 1.5
cm to 22 cm. However, malignancy in SPNs does not
correlate with tumor size [22]. Mean tumor size has
ranged from 4.7 to 9.5 cm in various studies [5, 8, 9, 12,
14, 16, 18, 23]. Tumor size in our resection specimens
ranged from 3 to 14 cm with mean size of 9.5 cm. Tu-
mors located in the distal body and tail tend to be larger
[24]. Apart from enucleation, distal pancreatectomy and
pancreaticoduodenectomy (Whipple’s resection) are also
commonly used to treat SPNs [11, 14, 16, 25]. More
than 90% patients undergo primary tumor resection [11,
12]. Histological and/or cytological evaluation remain
the gold standard in reaching a definitive diagnosis [26].
Histologically, SPNs show solid sheets of tumor cells
along with areas showing cells oriented around delicate
fibrovascular cores [1]. Periodic acid Schiff (PAS) posi-
tive hyaline globules constitute a common and typical
feature. Mitoses are usually rare, atypical mitoses are not
seen and MIB-1 (KI-67) proliferative index is very low
[5]. Histologically, the majority of SPNs run a benign
course and 5-year survival rates are excellent [5, 12–15].
We have diagnosed a number of these tumors over the
last two decades. However, in recent years we have
observed in our practice that the majority of SPNs were
reported in patients younger than 20 years of age. The
aim of the present study was to describe the clinico-
epidemiological as well as morphologic and immunohis-
tochemical (IHC) findings and behavior of SPNs
diagnosed in our practice. We also aim to present a de-
tailed review of published literature regarding the histo-
genesis, clinico-pathological features with emphasis on
newer IHC antibodies such as Transcription Factor E3
(TFE3), differential diagnostic considerations, thera-
peutic strategies, prognosis and biological behavior in-
cluding the likelihood of malignancy and the factors
which may be important in determining aggressive be-
havior in these tumors based on published literature.
Materials and methods
A total of 29 cases in patients under 20 years of age
reported as SPN of pancreas reported in the Section of
Histopathology, Department of Pathology and Laboratory
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Medicine, Aga Khan University Hospital Karachi during
the period January 2014 to December 2019 were included
in the study. These included 19 resection specimens, 4 in-
cisional biopsies and 6 cases received as blocks for second
opinion.
Preparation of tissue samples
Tru cut and incisional biopsies as well as resections
were fixed in 10% buffered formalin. All tru cut and
incisional biopsies were entirely submitted for histo-
logical examination. In case of resections (distal
pancreatectomy, pancreaticoduodenectomy or Whip-
ple Resection), multiple representative sections were
submitted, as per established protocols, from the
tumor, adjacent areas, resection margins and lymph
nodes (if present).
Pathological analysis
In all cases the initial diagnosis made by the primary
pathologist (to whom case was originally assigned) was
reviewed, considering the rarity of these tumors, by one
or more pathologists with special interest and expertise
in gastrointestinal, biliary and pancreatic pathology (ND
and ZA, the senior authors of this paper) before the case
was finally signed out.
IHC staining
Primary and reviewing pathologists performed a number
of IHC stains to complement the histological diagnosis
and to eliminate close histological mimics. IHC stains
commonly performed included CD10, CD56, beta ca-
tenin, Cyclin D1, CD99, Cytokeratins, Chromogranin A,
Synaptophysin and Progesterone Receptor (PR). Since
acquiring TFE3, this antibody was also commonly per-
formed. The large IHC panel helped in reaching an ac-
curate diagnosis.
Hematoxylin and eosin (H&E) slides as well as IHC
slides of all cases were retrieved and reviewed by the au-
thors. The two senior authors (ND & ZA) who have spe-
cial interest and expertise in Gastrointestinal, biliary
tract and pancreatic pathology, reviewed the histologic
and IHC features of all 29 cases.
Definitions of histological features
Solid tumor component in SPNs was defined as being
composed of poorly cohesive monomorphic cells that
cling to hyalinized or myxoid fibrovascular cords.
Pseudopapillae in SPNs are formed when the neoplas-
tic cells detach from fibrovascular stalks. Hyaline
globules in SPNs are defined as intracytoplasmic PAS
positive round eosinophilic bodies. These constitute a
common, although nonspecific histological feature
which can be useful in formulating a differential diag-
nosis in these tumors. Nuclear grooves in SPNs are
defined as longitudinal invaginations or indentations
of the nuclear envelope bilayer and are another com-
mon histologic feature of these tumors. Clear cells in
SPNs are defined as cells with abundant clear cyto-
plasm. SPNs composed predominantly of clear cells
are termed ‘clear cell variant’. Clear cells are multiva-
cuolated, do not contain glycogen, lipid or mucin and
seem to be formed as a result of dilatation of endo-
plasmic reticulum and mitochondria. Cystic degener-
ation involving < 5% of the tumor is common in
SPNs. SPNs with greater than 5% cystic degeneration
are termed the “microcystic variant”. Large atypical
pleomorphic cells and multinucleated tumor giant
cells (with multiple, enlarged hyperchromatic irregular
nuclei and abundant eosinophilic cytoplasm) are
typically present in the solid areas of SPN in a back-
ground of monomorphic cells. They probably repre-
sent degenerative changes in tumor cells and do not
appear to affect the prognosis.
IHC preparation
In IHC, special emphasis was placed on expression of
TFE3 (Cell Marque anti - TFE3, MRQ-37, rabbit mono-
clonal primary antibody, Rocklin, CA 95677 USA),
CyclinD-1 (FLEX Monoclonal Rabbit Anti-Human Cyc-
lin- D1 clone EP12, ready to use, Dako Denmark,
Glostrup, Denmark, Deko North America, Carpinteria,
California USA), CD56 (FLEX Monoclonal Mouse Anti
– Human CD56 clone 123C3 ready to use Dako
Denmark, Glostrup, Denmark), beta catenin (FLEX
Monoclonal Mouse Anti-Human beta Catenin Clone
beta catenin-1, ready to use, Dako Denmark, Glostrup,
Denmark), PR (FLEX Monoclonal Mouse Anti-Human
Progesterone Receptor Clone PgR 636 ready to use,
Dako Denmark, Glostrup, Denmark, Dako North Amer-
ica, Carpinteria, California USA), and CD99 (FLEX
Monoclonal Mouse Anti-Human CD99, MK2 Gene
Product Ewing’s Sarcoma Marker Clone 12E7 ready to
use, Dako Denmark, Glostrup, Denmark) by tumor cells.
For IHC testing, envision flex Immunohistochemistry
method was used. Envision Flex peroxidase bleaching re-
agent was applied against the slide for 5 min after which
slides were washed with wash buffer. Primary antibody)
was then applied to the tissue for 25 to 30min and
washed again with wash buffer. Then Envision Flex /
HRP (Secondary antibody was applied to the tissue for
25 to 30min and washed with wash buffer. Following
this, Envision Flex DAB + chromogen diluted in Envi-
sion flex substrate buffer was applied for 5 to 10 min
and washed with wash buffer. Slides were then counter-
stained with Hematoxylin, washed with buffer and dis-
tilled water. Slides were then dehydrated (alcohol to
xylene) and mounted in cover slipper.
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Histological features
Histological features including presence of pseudo papil-
lary architecture, microcystic change, presence of clear
cells, hyaline globules, nuclear grooves, eosinophilic
cytoplasm, myxoid stroma, atypical cells and tumor giant
cells, mitotic activity, calcification, cholesterol clefts, fi-
brosis, hemorrhage, infarction and tumor necrosis were
carefully noted.
Statistical analysis
Clinical data including age, gender, specific tumor loca-
tion in pancreas, size of tumor, type of surgery, lymph
node status and clinical follow up were obtained.
Statistical analysis was performed using SPSS version
27.0 to compare clinicopathological features and prog-
nosis between SPNs in patients above 20 and patients
under 20 years of age. Chi-square and Fisher’s exact tests
were performed. p-value < 0.05 was considered statisti-
cally significant.
Results
Epidemiological data and types of specimens in patients
above 20 years of age
During the period of study, 21 cases of SPN were re-
ported in patients above 20 years of age. Ages of patients
ranged from 22 to 49 years. Twenty patients (95.2%)
were females. In 15 cases (71.4%), pancreatic resection
specimens were received. Three cases (14.3%) were re-
ceived as incisional biopsies while 3 cases (14.3%) were
received as blocks for second opinion from other hospi-
tals. Nine out of 21 cases (42.8%) were in the tail of pan-
creas, 2 cases (9.5%) were located in the body and 1
(4.8%) in the uncinate process. In the 3 cases received as
blocks for second opinion, exact location was not
known. Of the 15 resection specimens, 8 (53.5%) were
distal pancreatectomies, while 7(46.7%) were Whipple
resections.
Tumor size, gross appearance and tumor extent in
patients above 20
Tumors ranged from 3.5 to 15 cm in largest dimension
with mean size of 7.0 cm. In 14 out of 15 resection spec-
imens (93.3%), tumor was confined to the pancreas and
resection margins were clear. Gross appearance was
similar to that seen in SPNs under 20 years. Histological
features in patients above 20 are summarized in Table 1.
Epidemiological data and types of specimens in patients
under 20
A total of 29 cases in patients under 20 years of age were
included in the study. Ages of the patients ranged from
12 to 19 years. Twenty-eight out of 29 patients (96.5%)
were females. In 19 out of 29 cases (65.5%), pancreatic
resection specimens were received. In 4 cases (13.8%),
incision biopsies were received. The remaining 6 cases
(20.7%) were received as blocks for second opinion with
primary diagnosis having been made at other institu-
tions. These included 5 incisional biopsies and 1 resec-
tion (distal pancreatectomy). In case of the resection
specimen, only representative blocks from tumor were
received.
Tumor location was tail of the pancreas in 11 cases
(37.9%), head of pancreas in 8 cases (27.6%), body in 4
cases (13.8%) and the uncinate process in 1 case (3.5%).
In 5 cases (17.2%) which were received as blocks for sec-
ond opinion, exact location of the tumor was not known.
Abdominal pain, mainly centered in epigastrium, was
the commonest clinical symptom. Of the 19 resection
specimens, 10 (52.6%) were partial (distal) pancreatecto-
mies while 9 (47.4%) were pancreaticoduodenectomies
(Whipple resections).
Tumor size, gross appearance and tumor extent in
patients under 20
Tumor size ranged from 3 cm to 14 cm in the largest
dimension with a mean size of 9.5 cm. In 17 out of 19
resection specimens (89.5%), tumor was confined to the
pancreas and resection margins were negative with
distances ranging from 0.2 to 1.5 cm. In 2 cases, tumor
extended beyond the pancreas and involved splenic
Table 1 Histological features of SPNs in patients above 20 years
(n = 21)




Pseudopapillary architecture 21 100%
Solid areas 21 100%
Eosinophilic cytoplasm 16 76.2%




Foamy/ hemosiderin laden macrophages 12 57.1%
Clear cells 15 71.4%
Hyaline globules 16 76.2%
Necrosis 5 23.8%
Cholesterol clefts 5 23.8%
Cystic degeneration 12 57.1%
Microcystic change 11 52.4%
Nuclear grooves 10 47.6%
Mitotic activity 3 14.3%
Atypical cells 3 14.3%
Giant cells 2 9.5%
Calcification 3 14.3%
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hilum and duodenal wall respectively. Lymph nodes
were recovered in 5 out of 19 cases (26.3%). Average
number of recovered lymph nodes was 13 per case. Two
out of 29 cases (6.9%) had evidence of distant metasta-
ses. One of these tumors was located in the tail of the
pancreas and metastasized to the liver while the other
tumor was located in the head of pancreas and metasta-
sized to the omentum. Grossly, the tumors were nodu-
lar, circumscribed, partly or wholly encapsulated lesions
with gray white solid cut surfaces. Tumors were firm to
friable in consistency and cut surfaces in most cases
showed hemorrhagic, infarcted and necrotic areas, foci
of cystic degeneration and cavitation (Fig. 1).
Histological features
A combination of solid and pseudopapillary areas was
seen histologically in all 29 cases (Fig. 2a, b, c). Cystic
degeneration was seen in 3 cases (10.3%). Cytoplasm was
eosinophilic in 23 cases (79.3%), and eosinophilic to
clear (Fig. 2d) in 6 cases (20.7%). No significant nuclear
atypia or mitotic activity was seen in any of our cases.
Nuclear grooves, hyaline globules (Fig. 3a) and foamy
histiocytes (Fig. 3b) were seen in 6 (20.7%), 9 (31.1%)
and 17 (58.6%) cases respectively. Microcystic change
(Fig. 3c) was noted in 7 cases. Involvement of the duo-
denal wall was seen in one case (Fig. 3d). The histo-
logical features of all 29 cases under 20 are summarized
in Table 2.
IHC expression
IHC stain for TFE3 (Fig. 4a) was performed in 21 cases
and demonstrated positivity in 12 cases (57.1%). Cyclin
D1 (Fig. 4b) was performed in 13 cases and was positive
in 12 (92.3%). Beta catenin (Fig. 4c) was performed in 16
cases and was positive in 15 (93.7%). Cytoplasmic dot
like positivity of CD99 (Fig. 4d) was noted in all 6
(100%) cases in which it was performed. CD56 (Fig. 5a)
and PR (Fig. 5b) were positive in 19 and 13 cases re-
spectively. The details of all IHC stains performed are
shown in Table 3. Clinical follow up was available in 14
out of 29 cases (48.3%). Of these 14 patients, 12 (85.7%)
were alive and well without evidence of recurrence and /
or metastasis for follow up durations ranging from 5 to
60months’ post-surgical resection. Median follow up
time was 26months. Two out of 14 patients (14.3%)
were alive but developed recurrence and metastases to
liver and omentum respectively 41- and 9-months post
resection. Six out of 14 patients (42.8%) received on
average 3 to 6 cycles of chemotherapy post-surgical re-
section. The remaining 8 patients did not receive
chemotherapy or any other treatment post resection.
However, 3 of these 8 patients were scheduled to
undergo chemotherapy which was delayed due to the
lock down imposed in the wake of the Covid-19
pandemic. These include 1 patient who developed
omental metastases 9 months’ post resection and 2 pa-
tients with direct involvement of duodenal wall and
splenic hilum 5- and 17-months post resection respect-
ively. All 14 patients were being followed up clinically by
means of CT scans yearly. The details of follow up are
summarized in Table 4.
Follow up
Follow up in patients above 20 years of age was available
in 11 out of 21 cases (52.4%). Follow up period ranged
from 3months to 70months. 10 (90.9%) patients were
alive and well. One patient had developed metastatic dis-
ease on initial follow up but was later lost to follow up.
Differences in SPNs in patients above 20 and under 20
years of age in tumors located in tail and head of pancreas
were not statistically significant (p-value 0.829 for both).
However, differences in tumor size were statistically sig-
nificant (p-value 0.0001). No significant statistical differ-
ence was found in the above 20 and under 20 group as
regard s tumor confined to pancreas (p-value 0.881). Simi-
larly, no significant statistical difference in prognosis were
found in both age groups (p-value 0.987).
Except for tumor size, no statistically significant differ-
ences in clinicopathological features or prognosis were
observed between SPNs occurring in patients over 20
and those under 20 years of age. Regarding tumor size,
larger number of cases in both age groups need to be
evaluated.
Discussion
SPNs should be considered in the differential diagnosis
of any solid or partly cystic pancreatic neoplasm in
Fig. 1 Gross appearance of SPN. Well circumscribed mass in head of
pancreas. Cut surface is partly solid with focal hemorrhagic and
cystic areas
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Fig. 2 a Pseudopapillary structures are a prominent feature in SPN. Tumor cells with eosinophilic cytoplasm are arranged around delicate
fibrovascular cores b Fibrovascular cores often demonstrate a myxoid stroma. c Solid sheets of tumor cells. Some vascular cores can be seen. d
Cells with clear cytoplasm
Fig. 3 a A number of eosinophilic hyaline globules are seen in the cytoplasm of tumor cells b Collections of foamy histiocytes are often seen. c
Focal microcystic areas are not an infrequent feature. d A tumor in our series seen involving duodenal wall
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Table 2 Histological features of SPN in patients under 20 years of age (n = 29)
Histological features Resection specimens
(n = 20)
Incision biopsies (n = 9)
Number of cases present Percentage (%) Number of cases present Percentage (%)
Pseudopapillary architecture 20 100% 9 100%
Solid areas 20 100% 9 100%
Eosinophilic cytoplasm 16 80% 7 77.7%
Myxoid stroma 16 80% 7 77.7%
Hemorrhage 15 75% 7 77.7%
Infarction 14 70% 6 66.7%
Fibrosis 14 70% 6 66.7%
Foamy/ hemosiderin laden macrophages 12 60% 5 55.5%
Clear cells 9 45% 4 44.4%
Hyaline globules 6 30% 3 33.3%
Necrosis 8 40% 4 44.4%
Cholesterol clefts 7 35% 3 33.3%
Cystic degeneration 2 10% 1 11.1%
Microcystic change 5 25% 2 22.2%
Nuclear grooves 5 25% 2 22.2%
Mitotic activity 5 25% 3 33.3%
Atypical cells 3 15% 2 22.2%
Giant cells 4 20% 2 22.2%
Calcification 3 15% 1 11.1%
Fig. 4 Immunohistochemistry in SPN. a Nuclear positivity for TFE3 b Diffuse strong nuclear positivity for Cyclin D1 c Nuclear positivity for beta
catenin d Cytoplasmic dot-like positivity for CD99 may demonstrate a unique staining pattern for diagnosis of SPNs
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young women under 35 years of age. In our study, tail
was the commonest location followed by the head. A
2018 study reported a complication rate of 21% follow-
ing surgery [23]. SPNs may show extensive necrotic and
hemorrhagic areas on cut surface especially when tu-
mors are large. Tumors often have a rubbery consistency
and cut surface is characteristically spongy [5]. Of the 19
resection specimens in our series, cut surface in most
cases showed areas of hemorrhage, infarction, necrosis,
cystic degeneration and cavitation (spongy appearance).
In Dubova et al’s series, hemorrhagic foci and blood-
filled cavities were seen in 40% cases [9].
Direct splenic invasion can occur in pancreatic tail
SPNs [24]. In our series, 1 case located in the tail dem-
onstrated direct splenic invasion. Histologically all 29
cases in our series showed areas with solid sheets of
tumor cells and other areas composed of pseudopapillary
structures. Solid areas are predominantly found near the
capsule of the tumor while pseudopapillae are more
common in the central part of the tumor. Tumor cells
were poorly cohesive and uniformly arranged around
delicate fibrovascular stalks [9]. Tumor cells in our cases
were round and monomorphic with oval, frequently
grooved nuclei, peripheral nucleoli and pale to clear
cytoplasm. Hyaline globules are seen in some cases.
These constitute a common and typical feature of SPNs,
although they are not specific to these tumors [5, 27].
Cholesterol clefts were also seen in multiple cases. Other
histologic features which are evaluated were based on
the histologic features described in the 5th edition of
WHO Classification of Digestive Tumors and other
studies and other studies included myxoid stroma, calci-
fication, aggregates of foamy histiocytes, eosinophilic
bodies, multinucleated cells, and clear cells. The results
are shown in Table 1. Except for clear cells, none of the
other histologic features are significantly associated with
aggressive behavior. Clear cells, when present, may be a
possible prognostic indicator for the presence of peri-
neural invasion which in turn is a predictive parameter
associated with aggressive behavior in these neoplasms
[28]. Areas of hemorrhage and infarction were seen in
75.9 and 72.4% of our cases, respectively. Hemorrhagic
areas are more common in large tumors. A study dem-
onstrated microcystic pattern in almost 30% SPNs
(microcystic SPNs) which may lead to confusion with
microcystic pancreatic neoplasms. The study found that
Fig. 5 Immunohistochemistry in SPN. a Membranous positivity for CD56 and b Strong nuclear positivity for PR
Table 3 Immunohistochemical profile of SPN cases in patients under 20 years of age (n = 29)
S. No Immunohistochemical Antibody No of cases in which performed Positive Type of staining Negative
1 TFE3 21 12(57.2%) Nuclear 9(42.8%)
2 Cyclin D1 13 12(92.3%) Nuclear 1(7.7%)
3 Beta Catenin 16 15(93.8%) Nuclear 1(6.2%)
4 CD99 (mic2) 6 6(100%) Cytoplasmic dot-like –
5 CD10 25 25(100%) Cytoplasmic –
6 CD56 19 19(100%) Membranous –
7 Progesterone Receptor (PR) 13 13(100%) Nuclear –
8 Vimentin 8 8(100%) Cytoplasmic –
9 Cytokeratin AE1/AE3 26 19(73.1%) Cytoplasmic 7(26.9%)
10 Chromogranin A 10 2(20%) Cytoplasmic 8(80%)
11 Synaptophysin 22 13(59.1%) Cytoplasmic 9(40.9%)
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clear cell change, hyalinized stroma and hemorrhage
were significantly more common in microcystic than
conventional SPNs and that microcystic SPNs were
much less likely to express IHC markers CD10 and
CD56 [29]. We observed microcystic pattern in 24.1% of
our cases (Table 1). SPNs demonstrate little or no obvi-
ous nuclear atypia and mitoses are rare. A recent study
found 0 to 6 mitoses per 20 HPFs. MIB-1 (KI-67) prolif-
erative index was very low [5]. Nuclear atypia and mi-
totic activity were insignificant in our cases.
The results of IHC staining in our cases are shown in
Table 2. Published literature has shown that almost all
SPNs demonstrate positivity for vimentin, CD10, CD56,
CD99, and alpha- 1 antitrypsin [10, 21, 30–32]. Peri-
nuclear dot like staining for CD99 constitutes a unique
staining pattern for diagnosing pancreatic SPNs [5, 7, 32,
33]. Numerous studies over the years have also docu-
mented the role of IHC stains such as beta catenin, Cyc-
lin D-1, FLI-1 and E- Cadherin in SPNs [5, 7, 9, 34]. A
number of studies including proteomic profiling studies
have underlined the importance of disrupted WNT/beta
catenin signaling pathways with concomitant cyclin D1
overexpression in the development of pancreatic SPNs.
SPNs consistently demonstrate B- catenin mutation with
activation of WNT- signaling pathway and resultant
overexpression of Cyclin D-1. Cyclin D1, FLI -1, CD56
and PR which are all expressed in SPNs are all localized
to chromosome 11 q [5, 35–38]. Beta catenin was
present in 16 cases, 1 out of these 16 cases did not show
beta catenin expression. However, this case showed the
classic histologic features of SPN and demonstrated
positivity for IHC stains of CD10, Cyclin D1, CD56, and
CD99. Owing to negativity for beta catenin, this case
was reviewed in the Intradepartmental Consultation
Conference attended by all consultants in the depart-
ment and a consensus was the consultants that it should
be reported as SPN in spite of negativity for beta
catenin.
SPNs have been shown to harbor recurrent somatic
pathogenic variants in the beta catenin gene, CTNNB1
and these contribute to the pathogenesis of these tumors
via the WNT signaling pathway. The activated WNT-
signaling pathway is disrupted due to beta catenin muta-
tion [35]. Free beta catenin regulates the WNT pathway
by undergoing rapid degeneration. Mutated beta catenin
does not undergo degradation resulting in disruption of
the WNT pathway. Beta catenin also normally play a
role in the coupling of cadherin to the cytoskeleton. E-
Cadherin is a member of the transmembrane
glycoprotein family which facilitates calcium mediated
intercellular adhesion. Mutated beta catenin also causes
mutations in E-cadherin gene resulting in abnormal ex-
pression of E- cadherin which can be confirmed by IHC.
Mutations in E- cadherin gene lead to disturbances in
cell adhesion in SPNs and lead to formation of pseudo-
papillary structures [9, 10, 34]. Nuclear expression of
Cyclin D-1 and E-cadherin is seen in 70 to 100% SPNs.
Similarly, beta catenin expression is seen in the large
majority of SPNs [10, 15, 18, 27, 34]. The nuclear label-
ing of beta catenin in SPNs helps in differentiation from
the membranous labeling seen in Pancreatic Neuroendo-
crine Tumors (Pan NETs) [15, 18].
It is clear from the above discussion that practically all
SPNs are positive for vimentin, beta catenin, cyclin D-1,
alpha-1 antitrypsin and CD56 and are typically negative
for E-cadherin [5, 10, 29, 33, 39]. PR negativity in SPNs
is associated with worse prognosis. Most cases demon-
strated positivity for PR. PR was performed in 13 of our
Table 4 Details of follow-up of SPN cases in patients under 20 years of age (n = 14)
S. No Year of resection Age Sex Treatment received Alive Recurrence / metastasis Length of Follow Up
1 2015 19 F Received chemotherapy Yes No 70months
2 2016 18 M Received chemotherapy Yes No 52months
3 2016 13 F No additional treatment received Yes No 48months
4 2016 18 F No additional treatment received Yes No 45months
5 2017 12 F Received 3 cycles of chemotherapy Yes Liver Metastasis 41 months
6 2017 17 F Received chemotherapy Yes No 39months
7 2017 17 F No additional treatment received Yes No 30months
8 2018 15 F Received chemotherapy Yes No 26months
9 2018 14 F Received 6 cycles of chemotherapy Yes No 22months
10 2018 18 F No additional treatment received Yes No 19months
11 2018 14 F No additional treatment received Yes No 17months
12 2019 19 F No additional treatment received Yes No 14months
13 2019 15 F No additional treatment received Yes Omental Metastasis 09 months
14 2019 14 F No additional treatment received Yes No 05months
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cases and positivity was seen in all cases. Negative PR re-
sult in SPNs is significantly associated with poorer
disease-free survival (DFS) and disease specific survival
(DSS). Thus, negative PR staining on IHC is an inde-
pendent poor prognostic factor and appears to have a
role in predicting adverse outcome [8, 10, 39].
In recent years, several new IHC antibodies have be-
come available which are very valuable in the correct
diagnosis of SPNs and in differentiating them from other
pancreatic neoplasms. The most important of these is
TFE3. As discussed above, aberrant WNT signaling is a
hall mark of these tumors. TFE3 plays a critical role in
the activation and regulation of the WNT pathway and
has been shown to be implicated in SPN. Almost 95%
SPNs display moderate to intense nuclear accumulation
and expression of TFE3. On the other hand, about 15 to
25% Pan NETs, ductal adenocarcinomas and pancreatic
neuroendocrine carcinomas respectively show positivity
for TFE3. Thus, TFE3 can be useful along with beta ca-
tenin as a diagnostic marker for SPN and in differentiat-
ing it from other pancreatic neoplasms. Similarly, SOX
proteins are key modulators of the WNT/ beta catenin
signaling pathway. Recent RNA microarray and gene
regulatory network analyses have shown that SOX11
mRNA is consistently increased in SPNs but not in Pan
NETs or the normal pancreas. Harrison et al. analyzed
the IHC expression of TFE3, SOX 11 and beta catenin
in 31 cases of surgically resected SPNs using Pan NETs,
acinar cell carcinomas and pancreatoblastomas as con-
trols. Positivity for TFE3 was seen in 30 out of 31 cases
(96.8%). Nuclear positivity for SOX-11 was seen in all 31
SPNs and in 5 out of 31 control tumors. Nuclear positiv-
ity for beta catenin was noted in all 31 SPNs and 4 con-
trol tumors. The combination of these three markers
can be used clinically as a diagnostic IHC panel in dis-
tinguishing SPNs in indeterminate cases from other pan-
creatic tumors which may mimic them histologically.
SOX11 and TFE3 can be useful as diagnostic markers
for SPNs in fine needle aspiration (FNA) biopsies as
well. These markers are useful as diagnostic markers for
distinguishing SPNs from their cytologic mimics. Kim
et al. also investigated the role of TFE3, LEF1 (lymphoid
enhancer binding factor 1), Androgen Receptor (AR)
and beta catenin in pancreatic SPNs. Positivity for TFE3
was seen in 68 out of 91 cases (74.7%). They reported
diffuse nuclear expression of beta catenin as a putative
diagnostic feature of SPN in almost 99% cases. LEF1 and
AR were also expressed in majority of SPNs, while pan-
creatic ductal adenocarcinomas and pan NETs showed
no expression. A combined IHC panel of beta catenin,
LEF1 and TFE3 resulted in a sensitivity and specificity of
100 and 91.9% in distinguishing SPNs from ductal
adenocarcinomas and Pan NETs. Thus, SOX11 and
other transcription factors are important in the diagnosis
of SPNs and in distinguishing them from Pan NETs and
pancreatic ductal adenocarcinomas. The above discus-
sion makes it clear that the combination of several IHC
markers ensures accurate diagnosis of SPNs and reduces
the chances of misdiagnosis [15, 18, 37, 39].
A recent study by Walters et al. compared pediatric
and adult SPNs and found that there were similarities in
demographics, tumor characteristics and treatment mo-
dalities. However, survival was shown to better in chil-
dren [40].
Although SPNs are considered to have low grade ma-
lignant potential, majority of cases are cured following
complete surgical resection and 5-year survival rates are
excellent [41–44]. About 10 to 15% of cases may demon-
strate malignant behavior characterized by tumor recur-
rence, invasion of adjacent organs and/ or metastasis
[45–47]. Surprisingly, one recent study showed histo-
logic features consistent with poor prognosis in large
majority of SPNs [48]. However, even tumors with ma-
lignant features are associated with excellent prognosis
and patients can be expected to have long survival fol-
lowing aggressive surgery [49]. A French study on
pediatric SPNs by Irtan et al. also showed tumor recur-
rence in pediatric SPNs also constitutes a rare and late
event and does not undermine overall survival.
Complete surgical resection appears to be the best op-
tion for recurrent tumors in the pediatric age group as
well. Enbloc resection without formal lymphadenectomy
is preferred and attempts should be made even to resect
distant metastases when present [50, 51].
Six out of 14 patients in our series, in whom follow up
was available, received chemotherapy post-surgery. An-
other 3 recent cases (1 with omental metastases and 2
with direct extension to duodenum and spleen respect-
ively) were scheduled to receive chemotherapy which
was delayed due to lockdowns imposed in the wake of
the Covid-19 pandemic. Questions can justifiably be
raised as to why 5 young patients whose tumors were
confined to the pancreas and were adequately resected
were given chemotherapy post resection. The possible
explanation is that many oncologists in our country (es-
pecially in smaller cities) have little knowledge of these
rare neoplasms and believe that being low grade malig-
nancies which can sometimes invade adjacent organs
and metastasize should be treated aggressively to achieve
good long term prognosis in young patients. In presence
of radical resection with negative margins, no adjuvant
oncological treatment is usually indicated in SPNs as
rate of recurrence is very low [17, 25]. Unresectable tu-
mors and metastases occurring within 36months are in-
dependent variables in predicting survival. Completely
resected tumors, even those showing aggressive gross
and morphologic features have excellent prognosis and
patients can still survive for more than 10 years [52, 53].
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SPNs have in the past been considered “benign” or “bor-
derline tumors” but recent molecular evidence demon-
strating alterations in cancer associated genes and the
ability of these tumors to metastasize have confirmed
their malignant nature [54]. Long term follow-up is
mandatory in order to detect delayed metastases [38].
Conclusions
Clinico-epidemiological, morphologic and IHC findings
of these rare tumors in patients under 20 years of age
are presented. The importance of a detailed IHC panel
in differentiating these tumors from histologic mimics
and reaching an accurate diagnosis is highlighted.
Factors affecting prognosis and predictive of aggressive
behavior (histological, IHC, clinical, and type of surgery)
are discussed. A detailed review of published literature is
presented to provide readers a comprehensive yet suc-
cinct account of these rare pancreatic neoplasms. Al-
though many studies on SPNs have been published,
surgeons, oncologists and even pathologists in this part
of the world are often not aware of these rare tumors
leading to inaccuracies and delays in diagnosis. In
addition, this paper focusses on the interesting observa-
tion that the majority of SPNs diagnosed in our depart-
ment during study period occurred in patients under 20
years of age (29 versus 21 in patients over 20). However,
clinico-epidemiological, morphologic and prognostic fea-
tures were similar in both age groups. New antibodies
such as TFE3 and prognostic importance of PR in SPNs
are also discussed. We believe that this is a very interest-
ing and helpful study for the clinicians as well as the pa-
thologists. Possibility of SPNs should always be
considered in case of pancreatic neoplasms occurring in
patients under 20 years of age as well.
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